United States Biotechnology & Medical Research

Damora Therapeutics Inc (Pre-Reincorporation) (DMRA)

Damora Therapeutics Inc witnessed a notable purchase by CEO Jennifer Jarrett, who acquired shares valued at $252,875 in late September. This activity contrasts with earlier divestments by other officers. Despite a 25% decline in stock price over the last quarter, these transactions precede the upcoming November 2026 earnings report.
Ticker: DMRA Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Damora Therapeutics Inc (Pre-Reincorporation). Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.6
Jarrett Jennifer Director, President and CEO Executive Director
Transaction date
Purchase
Price
478.95
Quantity 65,873 -46.7%
Value US$3,969,257
2.2
Firmani Lori Officer Officer
Transaction date
Proposed sale
Price
160.85
Quantity 22,929
Value US$3,767,681
1.9
Winslow Garrett General Counsel Officer
Transaction date
Sale
Price
404.16
Quantity 28,644 -11.9%
Value US$4,525,686
2.2
Firmani Lori Officer Officer
Transaction date
Proposed sale
Price
25.36
Quantity 7,615
Value US$193,140
2.2
Firmani Lori Officer Officer
Transaction date
Proposed sale
Price
25.36
Quantity 7,615
Value US$193,140
1.3
Schambye Hans T. Chief Executive Officer Executive Director
Transaction date
Sale
Price
21.38
Quantity 700 -13.0%
Value US$14,966
2.2
Firmani Lori Chief Financial Officer Officer
Transaction date
Sale
Price
21.41
Quantity 135 -12.7%
Value US$2,890
1.9
Winslow Garrett General Counsel Officer
Transaction date
Sale
Price
21.38
Quantity 255 -12.1%
Value US$5,452
1.3
Schambye Hans T. Chief Executive Officer Executive Director
Transaction date
Sale
Price
3.38
Quantity 735 -15.5%
Value US$2,484
2.2
Firmani Lori Interim CFO Officer
Transaction date
Sale
Price
3.39
Quantity 147 -17.5%
Value US$498
1.9
Winslow Garrett General Counsel Officer
Transaction date
Sale
Price
3.39
Quantity 260 -15.4%
Value US$881
2.2
Firmani Lori Interim CFO Officer
Transaction date
Sale
Price
5.63
Quantity 261 -36.0%
Value US$1,469
1.3
Schambye Hans T. Chief Executive Officer Executive Director
Transaction date
Sale
Price
5.60
Quantity 1,341 -28.3%
Value US$7,510
1.9
Winslow Garrett General Counsel Officer
Transaction date
Sale
Price
5.60
Quantity 471 -31.8%
Value US$2,638
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
0.75
Quantity 535,534 -26.2%
Value US$401,650
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
0.75
Quantity 248,819 -28.3%
Value US$186,614
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
0.75
Quantity 38,327 -28.3%
Value US$28,745
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
3.00
Quantity 153,078 -6.8%
Value US$459,234
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
3.00
Quantity 29,700 -3.3%
Value US$89,100
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
3.00
Quantity 26,622 -16.4%
Value US$79,866
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.92
Quantity 26,700 -1.2%
Value US$77,964
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.92
Quantity 4,700 -0.5%
Value US$13,724
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.92
Quantity 7,800 -4.6%
Value US$22,776
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.40
Quantity 132,100 -5.5%
Value US$317,040
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.40
Quantity 52,800 -5.5%
Value US$126,720
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
2.40
Quantity 9,800 -5.5%
Value US$23,520
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.97
Quantity 8,878 -0.4%
Value US$17,490
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.97
Quantity 3,551 -0.4%
Value US$6,995
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.97
Quantity 660 -0.4%
Value US$1,300
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.86
Quantity 28,110 -1.1%
Value US$52,285
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.86
Quantity 11,245 -1.1%
Value US$20,916
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.86
Quantity 2,091 -1.1%
Value US$3,889
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 9,459 -0.4%
Value US$17,215
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 3,784 -0.4%
Value US$6,887
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 703 -0.4%
Value US$1,279
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.81
Quantity 1,603 -0.1%
Value US$2,901
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.81
Quantity 641 -0.1%
Value US$1,160
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.81
Quantity 119 -0.1%
Value US$215
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 9,459 -0.4%
Value US$17,215
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 3,784 -0.4%
Value US$6,887
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.82
Quantity 703 -0.4%
Value US$1,279
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.79
Quantity 34,745 -1.4%
Value US$62,194
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.79
Quantity 13,899 -1.4%
Value US$24,879
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.79
Quantity 2,584 -1.4%
Value US$4,625
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-28 2026-09-25 B Purchase
3.6
Jarrett Jennifer

Director, President and CEO

Executive Director
65,873 -46.7%
478.95
US$3,969,257 		65,873 -46.7% 478.95 US$3,969,257
2026-08-06 2026-08-05 PrS Proposed sale
2.2
Firmani Lori

Officer

Officer
22,929
160.85
US$3,767,681 		22,929 160.85 US$3,767,681
2026-07-07 2026-07-06 S Sale
1.9
Winslow Garrett

General Counsel

Officer
28,644 -11.9%
404.16
US$4,525,686 		28,644 -11.9% 404.16 US$4,525,686
2026-06-22 2026-06-22 PrS Proposed sale
2.2
Firmani Lori

Officer

Officer
7,615
25.36
US$193,140 		7,615 25.36 US$193,140
2026-06-22 2026-06-22 PrS Proposed sale
2.2
Firmani Lori

Officer

Officer
7,615
25.36
US$193,140 		7,615 25.36 US$193,140
2026-01-06 2026-01-02 S Sale
1.3
Schambye Hans T.

Chief Executive Officer

Executive Director
700 -13.0%
21.38
US$14,966 		700 -13.0% 21.38 US$14,966
2026-01-06 2026-01-02 S Sale
2.2
Firmani Lori

Chief Financial Officer

Officer
135 -12.7%
21.41
US$2,890 		135 -12.7% 21.41 US$2,890
2026-01-06 2026-01-02 S Sale
1.9
Winslow Garrett

General Counsel

Officer
255 -12.1%
21.38
US$5,452 		255 -12.1% 21.38 US$5,452
2025-07-08 2025-07-03 S Sale
1.3
Schambye Hans T.

Chief Executive Officer

Executive Director
735 -15.5%
3.38
US$2,484 		735 -15.5% 3.38 US$2,484
2025-07-08 2025-07-03 S Sale
2.2
Firmani Lori

Interim CFO

Officer
147 -17.5%
3.39
US$498 		147 -17.5% 3.39 US$498
2025-07-08 2025-07-03 S Sale
1.9
Winslow Garrett

General Counsel

Officer
260 -15.4%
3.39
US$881 		260 -15.4% 3.39 US$881
2025-01-07 2025-01-03 S Sale
2.2
Firmani Lori

Interim CFO

Officer
261 -36.0%
5.63
US$1,469 		261 -36.0% 5.63 US$1,469
2025-01-07 2025-01-03 S Sale
1.3
Schambye Hans T.

Chief Executive Officer

Executive Director
1,341 -28.3%
5.60
US$7,510 		1,341 -28.3% 5.60 US$7,510
2025-01-07 2025-01-03 S Sale
1.9
Winslow Garrett

General Counsel

Officer
471 -31.8%
5.60
US$2,638 		471 -31.8% 5.60 US$2,638
2023-10-02 2023-10-02 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
57,312
0.72
US$41,265 		57,312 0.72 US$41,265
2023-10-02 2023-10-02 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
244,527
0.72
US$176,059 		244,527 0.72 US$176,059
2023-10-02 2023-10-02 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
37,675
0.72
US$27,126 		37,675 0.72 US$27,126
2023-10-02 2023-10-02 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
585,274
0.72
US$421,397 		585,274 0.72 US$421,397
2023-08-30 2023-08-30 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
119,679
0.58
US$69,414 		119,679 0.58 US$69,414
2023-08-30 2023-08-30 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
510,610
0.58
US$296,154 		510,610 0.58 US$296,154
2023-08-30 2023-08-30 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
78,659
0.58
US$45,622 		78,659 0.58 US$45,622
2023-08-30 2023-08-30 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
1,222,125
0.58
US$708,833 		1,222,125 0.58 US$708,833
2023-08-21 2023-08-21 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
97,204
0.62
US$59,975 		97,204 0.62 US$59,975
2023-08-21 2023-08-21 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
1,510,375
0.62
US$931,901 		1,510,375 0.62 US$931,901
2023-08-21 2023-08-21 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
147,910
0.62
US$91,260 		147,910 0.62 US$91,260
2023-08-21 2023-08-21 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
631,048
0.62
US$389,357 		631,048 0.62 US$389,357
2023-08-21 2023-08-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
75,473
0.75
US$56,605 		75,473 0.75 US$56,605
2023-08-17 2023-08-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
535,534 -26.2%
0.75
US$401,650 		535,534 -26.2% 0.75 US$401,650
2023-08-17 2023-08-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
248,819 -28.3%
0.75
US$186,614 		248,819 -28.3% 0.75 US$186,614
2023-08-17 2023-08-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
38,327 -28.3%
0.75
US$28,745 		38,327 -28.3% 0.75 US$28,745
2023-08-15 2023-08-15 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
114,843
0.75
US$86,132 		114,843 0.75 US$86,132
2023-08-15 2023-08-15 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
489,970
0.75
US$367,478 		489,970 0.75 US$367,478
2023-08-15 2023-08-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
1,172,714
0.75
US$879,536 		1,172,714 0.75 US$879,536
2023-08-15 2023-08-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
75,473
0.75
US$56,605 		75,473 0.75 US$56,605
2023-08-02 2023-07-31 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
153,078 -6.8%
3.00
US$459,234 		153,078 -6.8% 3.00 US$459,234
2023-08-02 2023-07-31 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
29,700 -3.3%
3.00
US$89,100 		29,700 -3.3% 3.00 US$89,100
2023-08-02 2023-07-31 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
26,622 -16.4%
3.00
US$79,866 		26,622 -16.4% 3.00 US$79,866
2023-07-31 2023-07-31 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
246,830
3.02
US$745,427 		246,830 3.02 US$745,427
2023-07-31 2023-07-31 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
180,300
3.02
US$544,506 		180,300 3.02 US$544,506
2023-07-31 2023-07-31 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
930,717
3.02
US$2,810,765 		930,717 3.02 US$2,810,765
2023-07-31 2023-07-31 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
162,153
3.02
US$489,702 		162,153 3.02 US$489,702
2023-07-27 2023-07-25 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
26,700 -1.2%
2.92
US$77,964 		26,700 -1.2% 2.92 US$77,964
2023-07-27 2023-07-25 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
4,700 -0.5%
2.92
US$13,724 		4,700 -0.5% 2.92 US$13,724
2023-07-27 2023-07-25 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
7,800 -4.6%
2.92
US$22,776 		7,800 -4.6% 2.92 US$22,776
2023-07-25 2023-07-25 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
8,100
2.35
US$19,035 		8,100 2.35 US$19,035
2023-07-25 2023-07-25 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
4,700
2.35
US$11,045 		4,700 2.35 US$11,045
2023-07-25 2023-07-25 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
26,700
2.35
US$62,745 		26,700 2.35 US$62,745
2023-07-25 2023-07-25 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
7,800
2.35
US$18,330 		7,800 2.35 US$18,330
2023-07-17 2023-07-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
132,100 -5.5%
2.40
US$317,040 		132,100 -5.5% 2.40 US$317,040
2023-07-17 2023-07-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
52,800 -5.5%
2.40
US$126,720 		52,800 -5.5% 2.40 US$126,720
2023-07-17 2023-07-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
9,800 -5.5%
2.40
US$23,520 		9,800 -5.5% 2.40 US$23,520
2023-07-13 2023-07-13 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
52,800
2.55
US$134,640 		52,800 2.55 US$134,640
2023-07-13 2023-07-13 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
14,700
2.55
US$37,485 		14,700 2.55 US$37,485
2023-07-13 2023-07-13 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
132,100
2.55
US$336,855 		132,100 2.55 US$336,855
2023-07-13 2023-07-13 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
9,800
2.55
US$24,990 		9,800 2.55 US$24,990
2023-04-17 2023-04-17 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
8,878 -0.4%
1.97
US$17,490 		8,878 -0.4% 1.97 US$17,490
2023-04-17 2023-04-17 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,551 -0.4%
1.97
US$6,995 		3,551 -0.4% 1.97 US$6,995
2023-04-17 2023-04-17 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
660 -0.4%
1.97
US$1,300 		660 -0.4% 1.97 US$1,300
2023-04-17 2023-04-14 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
28,110 -1.1%
1.86
US$52,285 		28,110 -1.1% 1.86 US$52,285
2023-04-17 2023-04-14 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
11,245 -1.1%
1.86
US$20,916 		11,245 -1.1% 1.86 US$20,916
2023-04-17 2023-04-14 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
2,091 -1.1%
1.86
US$3,889 		2,091 -1.1% 1.86 US$3,889
2023-04-17 2023-04-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
9,459 -0.4%
1.82
US$17,215 		9,459 -0.4% 1.82 US$17,215
2023-04-17 2023-04-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,784 -0.4%
1.82
US$6,887 		3,784 -0.4% 1.82 US$6,887
2023-04-17 2023-04-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
703 -0.4%
1.82
US$1,279 		703 -0.4% 1.82 US$1,279
2023-04-12 2023-04-12 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,603 -0.1%
1.81
US$2,901 		1,603 -0.1% 1.81 US$2,901
2023-04-12 2023-04-12 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
641 -0.1%
1.81
US$1,160 		641 -0.1% 1.81 US$1,160
2023-04-12 2023-04-12 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
119 -0.1%
1.81
US$215 		119 -0.1% 1.81 US$215
2023-04-12 2023-04-11 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
9,459 -0.4%
1.82
US$17,215 		9,459 -0.4% 1.82 US$17,215
2023-04-12 2023-04-11 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,784 -0.4%
1.82
US$6,887 		3,784 -0.4% 1.82 US$6,887
2023-04-12 2023-04-11 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
703 -0.4%
1.82
US$1,279 		703 -0.4% 1.82 US$1,279
2023-04-12 2023-04-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
34,745 -1.4%
1.79
US$62,194 		34,745 -1.4% 1.79 US$62,194
2023-04-12 2023-04-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
13,899 -1.4%
1.79
US$24,879 		13,899 -1.4% 1.79 US$24,879
2023-04-12 2023-04-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
2,584 -1.4%
1.79
US$4,625 		2,584 -1.4% 1.79 US$4,625
2023-04-10 2023-04-10 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
1,686
1.90
US$3,203 		1,686 1.90 US$3,203
2023-04-10 2023-04-10 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
2,512
1.90
US$4,773 		2,512 1.90 US$4,773

See older Damora Therapeutics Inc (Pre-Reincorporation) insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Damora Therapeutics Inc (Pre-Reincorporation) history with Plus

Billed monthly · Cancel anytime

Explore more

More insider trading research around Damora Therapeutics Inc (Pre-Reincorporation)

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America